Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:35 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 54 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Vasopressor Clear all

Conditions: Pre-eclampsia
Interventions: Phenylephrine, Ephedrine; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Septic Shock
Interventions: Dopamine, Norepinephrine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Septic Shock
Interventions: Not listed
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Shock
Interventions: Norepinephrine, Epinephrine, Phenylephrine, Vasopressin; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 836 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Epistaxis, Blood Pressure
Interventions: Oxymetazoline 0.05%, Phenylephrine 0.25%, Lidocaine 1% plus epinephrine 1:100,000, Bacteriostatic 0.9% NaCL; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Sepsis
Interventions: ECHO, Blood Draw; Procedure
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 7
States / cities: Boston, Massachusetts • The Bronx, New York • Winston-Salem, North Carolina + 4 more

Conditions: Intraoperative Hypotension
Interventions: E-Fusion Vasopressor Titration-Assist; Device
Lead sponsor: Autonomous Healthcare, Inc.; Industry
Eligibility: 22 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Septic Shock
Interventions: Midodrine Hydrochloride, placebo; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 89 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Hypotension and Shock
Interventions: VIGORIS Blood Pressure Management Clinical Decision Support System; Device
Lead sponsor: Andrew Tomas Reisner; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Septic Shock
Interventions: Angiotensin II; Drug
Lead sponsor: George Washington University; Other
Eligibility: 21 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Septic Shock, Shock, Sepsis, Systemic Inflammatory Response Syndrome
Interventions: Angiotensin II and hydrocortisone sodium succinate; Drug
Lead sponsor: Kingman Regional Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Kingman, Arizona

Conditions: Mechanical Ventilation Complication, Arterial Thrombosis, Limb Ischemia, Shock, Hypotension, Bloodstream Infection, Vasopressor Adverse Reaction, Renal Failure
Interventions: Restricted-use of arterial catheter, Standard-use of arterial catheter; Other
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Hypotension
Interventions: Phenylephrine, Norepinephrine; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Septic Shock
Interventions: Vasopressin, Recommendation to use a lower initiation threshold for vasopressin, Recommendation to use a higher initiation threshold for vasopressin; Drug · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 3,959 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 13
States / cities: Burley, Idaho • American Fork, Utah • Cedar City, Utah + 10 more

Conditions: Septic Shock, Acute Kidney Injury
Interventions: Standard of Care, Angiotensin II; Other · Drug
Lead sponsor: Alexander Flannery; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Ascites, Cirrhosis
Interventions: Albumin, Intravenous Saline Infusion (Albumin placebo), Midodrine, Oral tablet (Midodrine placebo), Octreotide LAR, Saline injection (Octreotide LAR placebo), Large Volume Paracentesis; Drug · Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 80 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: West Haven, Connecticut

Conditions: Respiratory Failure, Hypotension and Shock, Hypotension on Induction, Intubation Complication, Anesthesia Intubation Complication
Interventions: Norepinephrine, Lactated Ringers, Intravenous, normal saline, Plasma-lyte; Drug
Lead sponsor: Wright State University; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dayton, Ohio

Conditions: Sepsis, Septic Shock
Interventions: vasopressin - early initiation, vasopressin - standard initiation; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Catecholamine-resistant Hypotension (CRH), Distributive Shock, High Output Shock, Sepsis
Interventions: Angiotensin II; Drug
Lead sponsor: La Jolla Pharmaceutical Company; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Charlotte, North Carolina • Cincinnati, Ohio • San Antonio, Texas

Conditions: Sepsis, Hypotension
Interventions: Drotrecogin Alfa (Activated), placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Hypotension, Shock
Interventions: Vasopressors; Drug
Lead sponsor: Francois Lamontagne; Other
Eligibility: 17 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Anesthesia, Surgery With General Anesthesia, Noncardiac Surgery, Hypotension During Surgery, Acute Kidney Injury (AKI), Myocardial Injury After Noncardiac Surgery (MINS), Vasopressor
Interventions: Norepinephrine, Phenylephrine; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 18,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 9
States / cities: San Francisco, California • College Park, Maryland • Ann Arbor, Michigan + 6 more

Conditions: Sepsis
Interventions: Alirocumab, Placebo; Drug
Lead sponsor: Jonathan Sevransky; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Septic Shock
Interventions: Methylene Blue, Phenylephrine; Drug
Lead sponsor: Carilion Clinic; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Roanoke, Virginia

Search by objective public record fields.

Phenylephrine Versus Ephedrine in Pre-eclampsia

Dopamine Versus Norepinephrine for the Treatment of Vasopressor Dependent Septic Shock

Evaluating the Effect of Chronic Antihypertensive Therapy on Vasopressor Dosing in Septic Shock

Vasoactive Drugs in Intensive Care Unit

The Effect of Intranasal Vasoconstrictor Medications on Hemodynamic Parameters: A Randomized Double-blind, Placebo-controlled Trial.

Study of Treatment's Echocardiographic Mechanisms

Feasibility Study of E-Fusion Vasopressor Titration-Assist During Multi-Level Spine Surgery

Midodrine Use in Septic Shock

BP Management System User Acceptance Testing

Intravenous AII for the Treatment of Severe Hypotension in High Output Shock: A Pilot Study

Hemodynamic Response to Angiotensin-II When Used as the Second Vasopressor Agent for Septic Shock

Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment

Vasopressor Outcomes in Spine Surgery

Vasopressin for Septic Shock Pragmatic Trial

Renin and Renal Biomarker Response to Angiotensin II

Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis

Using Vasopressor Medication to Support Blood Pressure During Intubation Procedure

Early Versus Late Adjunctive Vasopressin in Septic Shock

A Study of LJPC-501 in Pediatric Patients With Hypotension

Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion

Optimal VAsopressor titraTION Pilot Randomized Controlled Trial

The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery

Alirocumab in Patients with Sepsis

Methylene Blue as a Third-line Vasopressor in Septic Shock